Immix Biopharma, Inc. IMMX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $16.26M+44.0% | $11.29M+29.3% | $8.74M+108% | $4.2M+3,216% | ||
| $13.7M+20.3% | $11.38M+53.7% | $7.41M+84.1% | $4.02M+228% | ||
| $29.96M+32.1% | $22.67M+40.5% | $16.14M+96.4% | $8.22M+508% | ||
| -$29.96M-32.1% | -$22.67M-40.5% | -$16.14M-96.4% | -$8.22M-508% | ||
| $555.53K-45.4% | $1.02M+77.9% | $572.01K— | —— | ||
| -$29.4M-35.8% | -$21.66M-39.1% | -$15.57M-89.4% | -$8.22M+66.3% | ||
| $37.72K-8.1% | $41.04K+55.4% | $26.42K+157% | $10.27K+70.8% | ||
| -$29.4M-36.0% | -$21.61M-40.1% | -$15.43M-87.4% | -$8.23M+66.2% | ||
| -$0.89-15.6% | -$0.77+13.5% | -$0.89-50.8% | -$0.59+91.1% | ||
| -$29.71M-31.2% | -$22.64M-40.3% | -$16.14M-96.4% | -$8.22M-509% | ||
| -$29.96M-32.1% | -$22.67M-40.5% | -$16.14M-96.4% | -$8.22M-508% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Immix Biopharma, Inc. profitable?
- Immix Biopharma, Inc. is not currently profitable: it reported a net loss of $34.9M over the trailing twelve months.
- What is Immix Biopharma, Inc.'s earnings per share?
- Immix Biopharma, Inc.'s diluted EPS over the trailing twelve months is $-0.92.
- Where does Immix Biopharma, Inc.'s income statement data come from?
- Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.